Tag: Clinical Trials
Granting Waiver for Cancer Treatment Does Not Affect Safety, Efficacy Outcomes
Similar serious adverse event rate, clinical benefit seen for patients with versus those without a waiver
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
89 percent of cancer centers report that cancer drugs are in short supply, most often vinblastine, etoposide, and topotecan
AI Screens Patients for Clinical Trials With Greater Accuracy Than Staff
In addition to enhanced performance, automated screening cuts costs
Survival Benefit for Cancer Trial Participants Does Not Persist in Adjusted Analyses
Survival benefits disappear when only high-quality studies are pooled and with adjustment for potential publication bias
Survival Gains Seen With Assignment to Experimental Group in Cancer Trials
Statistically significant survival gains observed for patients with solid tumors assigned to experimental group
Patient Enrollment in Cancer Treatment Trials About 7 Percent
One in five patients with cancer participate in any cancer-related trial, including biorepository, registry, genetic, and quality-of-life studies
Biological Agent Trials for Psoriasis Rarely Include Patient Images
A total of 203 images were shared depicting 60 patients, for an overall sharing rate of 0.1 percent
White Women Overrepresented in Gynecologic Cancer Trials
Underrepresentation seen among Asian and Hispanic women for all cancer sites, with variance for Black women by cancer site
Diversity in Early-Phase Cancer Trials Improved Since 2000
Some gains seen in racial/ethnic and geographic diversity; more older patients also enrolled
Survival Similar for Black, White Prostate Cancer Patients in Clinical Trial Setting
Median PFS, OS similar for Black and White patients receiving first- or second-generation androgen receptor pathway inhibitors
